Neuronetics schedules November 4 results for Neuronetics stock

Published on 10/29/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Its next report is set for November 4, 2026. Neuronetics stock costs EUR 2.03 on October 29, 2026 at Lang & Schwarz.

Operating scale and call details

Management's conference call is scheduled for 8:30 a.m. Eastern Time.
Neuronetics reports over 4.8 million NeuroStar treatment sessions in its corporate profile.
The company profile lists 658 full-time employees.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics (ISIN US64131A1051) plans to release its third-quarter 2026 financial and operating results on November 4, 2026. The company announced the schedule in an October 21 IR release. The date gives investors a defined checkpoint for the medical-device group's revenue trajectory and clinic strategy.

When does management speak?

The results are scheduled before the U.S. market opens, followed by a management conference call at 8:30 a.m. Eastern Time. The company release says the call will review the third-quarter results and will be available through a live webcast.

The reporting date matters because Neuronetics combines NeuroStar transcranial magnetic stimulation technology with direct patient care through its Greenbrook network. That combination makes revenue progression and clinic utilization central figures for the next update.

What supports the business case?

Neuronetics describes NeuroStar as an FDA-cleared, non-drug treatment system for major depressive disorder. Its investor-relations profile cites more than 4.8 million treatment sessions, a scale figure that supports the company's established commercial footprint while leaving the quarterly report to show how that footprint is translating into financial performance.

The company profile identifies 658 full-time employees and a healthcare business focused on medical devices. The November report should therefore provide the next dated evidence on operating execution, rather than relying on broad sector indicators. The scheduled call also gives management an opportunity to explain demand, treatment-center activity and the balance between technology sales and patient care.

Stock indication and investor context

Neuronetics is listed on Nasdaq under the ticker STIM. Its U.S. listing and the November reporting date provide the relevant framework for investors following the company from Germany, where the euro quotation offers a separate intraday reference.

The stock was trading at EUR 2.03 at Lang & Schwarz on October 29, 2026 at 1:27 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Neuronetics stock.